Relapsing-remitting multiple sclerosis is an unpredictable disease marked by relapses and remissions, but there are options ...

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering ...

Recent research highlights challenges with using PIRA and RAW as reliable trial outcomes in relapsing-remitting multiple ...

Age is a major modifier of inflammatory CSF signatures in MS. This finding identifies novel biomarker candidates and potential therapeutic targets.

In a 2017 study, researchers found evidence supporting the idea that MS fatigue can fluctuate in people living with relapsing-remitting MS for the same reasons that fatigue fluctuates in people ...